Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 14/20 | 0.36 |
| ▸ | HTR2A | P28223 | 12/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 12/20 | 0.35 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | PPARD | Q03181 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
| ▸ | VHL | P40337 | 1/20 | 0.32 |
| ▸ | ELOC | Q15369 | 1/20 | 0.32 |
| ▸ | ELOB | Q15370 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5501871 | 0.94 | SLC6A4 (0.39) | SLC6A4HTR2AKCNH2SOS1VHL | |
| Formic Acid SCHEMBL5999555 | 0.92 | SLC6A4 (0.42) | SLC6A4HTR2AKCNH2SOS1VHL | |
| SCHEMBL5502199 | 0.85 | SLC6A4 (0.46) | SLC6A4HTR2AKCNH2SOS1VHL | |
| Formic Acid SCHEMBL5999533 | 0.84 | HTR2A (0.55) | SLC6A4HTR2AKCNH2 | |
| Formic Acid SCHEMBL6000205 | 0.83 | PTGDR2 (0.37) | SLC6A4HTR2AKCNH2 | |
| Formic Acid SCHEMBL5998708 | 0.82 | SOS1 (0.39) | SLC6A4HTR2AKCNH2SOS1 | |
| SCHEMBL5999538 | 0.82 | SLC6A4 (0.37) | SLC6A4HTR2AKCNH2VHLELOC | |
| Formic Acid SCHEMBL6000548 | 0.82 | SLC6A4 (0.43) | SLC6A4HTR2AKCNH2SOS1 | |
| Formic Acid SCHEMBL5998672 | 0.80 | SOS1 (0.39) | SLC6A4HTR2AKCNH2SOS1 | |
| SCHEMBL5501867 | 0.77 | HTR2A (0.62) | SLC6A4HTR2AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060058361-A1 | Therapeutic diphenyl ether ligands | PFIZER INC | 2006-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058361-A1 | Therapeutic diphenyl ether ligands | HTR2B, HTR2C, HTR3B | SLC6A4 150/4885HTR2A 7/4885KCNH2 2331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.